GCTK GlucoTrack, Inc. Common Stock · XNAS
2.54 -21.4% as of Sep 11, 14:55 ET
fans
What's happening Live detector signal Generated 19:37 ET
Share structure
Free float
—, refreshing
2026-08-14
Shares out
798.1K
latest detail
Market cap
$2.6M
at ref price
Short interest
0.3%
2026-08-31
Float rotation
0.07×
latest snapshot
20d dollar vol
$771.9K
baseline
Supply intelligence
Gap quality
mixed supply · 52
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
low float
detector reason
Supply factor
nano-cap supply profile
detector reason
Supply factor
recent reverse split dilution risk
detector reason

This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.

Filings and news
2026-09-11 14:55 ETSignalGlucoTrack, Inc. Common Stock is down 21.4%, at 2.54, on $1.7M traded, 4.8× 20-day volume, 0.07× float rotation. Score 92. Primary driver: 7.2% float rotation. Supply intelligence: mixed supply · 52.
2026-09-118-KItem 1.01 — Entry into a material definitive agreement; Item 2.03 — Creation of a direct financial obligation +1 more SEC
2026-09-098-KItem 1.01 — Entry into a material definitive agreement; Item 2.03 — Creation of a direct financial obligation +1 more SEC
2026-08-31Split1-for-15 reverse split logged
2026-08-288-KItem 5.03 — Amendments to charter or bylaws; Item 8.01 — Other events +1 more SEC
2026-08-278-KItem 7.01 — Regulation FD disclosure; Item 9.01 — Financial statements and exhibits SEC
2026-08-198-KCurrent report filed with SEC. SEC
2026-08-1410-QQuarterly report SEC
2026-07-17 13:20 ETAnalyst RatingE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing News
2026-07-16 16:57 ETOfferingUPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform News
2026-05-14 17:27 ETFDA / ClinicalGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights News
2026-05-07 13:00 ETFDA / ClinicalGlucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology News
Latest detector signalscore 92
score 92